A Single Dose, Non-Randomized, Open-Label, Parallel Group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of MT-7117 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
Latest Information Update: 26 Apr 2023
At a glance
- Drugs Dersimelagon (Primary)
- Indications Autoimmune disorders; Erythropoietic protoporphyria
- Focus Pharmacokinetics
- Sponsors Mitsubishi Tanabe Pharma America
- 14 Dec 2021 Status changed from recruiting to completed.
- 02 Aug 2021 Planned End Date changed from 1 Jul 2021 to 1 Nov 2021.
- 02 Aug 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Nov 2021.